Cyclodextrin-Mediated Lipid Exchange for Red Blood Cell Shelf Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The short shelf life of red blood cells (RBCs) limits their availability for transfusions, leading to increased morbidity due to the degradation and phagocytosis of aged RBCs, which results in inflammation and reduced transfusion efficacy.
Innovation Solution
Exposing RBCs to a cyclodextrin composition containing exogenous lipids, such as phosphatidylcholines and sphingomyelins, to mediate lipid exchange on the outer membrane, thereby extending the shelf life of RBCs by reconstituting the lipid layer and reducing phagocytosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If red blood cells are stored for extended periods, then the availability of transfusable blood increases, but the RBCs undergo progressive degradation and become senescent, leading to increased phagocytosis and morbidity
Solution Approach 1:
The patent applies preliminary action by treating RBCs with cyclodextrin composition before storage to exchange lipids in advance. This pre-treatment modifies the membrane lipid composition prior to storage, preventing degradation and senescence that would otherwise occur during extended storage periods, thereby maintaining transfusion safety while extending shelf life.
Solution Approach 2:
The patent changes the physical-chemical parameters of the RBC membrane by exchanging native lipids with exogenous lipids (such as phosphatidylcholines and sphingomyelins) through cyclodextrin-mediated lipid exchange. This parameter change in membrane composition stabilizes the RBCs during storage, reducing degradation and phagocytosis while extending shelf life without compromising transfusion safety.
2Duration of action of stationary object
If RBCs are stored at refrigerated temperatures, then the shelf life is extended to 35-42 days, but the RBCs still undergo progressive degradation resulting in enhanced clearance rate from circulation
Solution Approach 1:
The patent uses cyclodextrin as an intermediary molecule to mediate lipid exchange between exogenous lipids and native RBC membrane lipids. This intermediary facilitates the replacement of degraded or vulnerable lipids with stable exogenous lipids, reducing degradation products and phagocytosis risk while maintaining extended storage duration at refrigerated temperatures.
Solution Approach 2:
The patent modifies the chemical composition parameters of the RBC membrane by introducing exogenous lipids with different physical-chemical properties. These parameter changes in lipid composition (such as increased sphingomyelin and phosphatidylcholine content) enhance membrane stability during refrigerated storage, reducing degradation and harmful byproducts while extending shelf life.
3Productivity
If the shelf life of RBCs is extended beyond 42 days, then more blood becomes available for transfusion, but the morbidity from transfusion increases due to monocyte/macrophage uptake
Solution Approach 1:
The patent applies preliminary action by performing lipid exchange treatment before storage to prevent senescence markers from developing. By pre-modifying the membrane composition with stable exogenous lipids, the RBCs resist phagocytosis by monocytes and macrophages even after extended storage, thereby increasing blood availability without increasing morbidity from inflammation and iron deposition.
Solution Approach 2:
The patent changes the membrane lipid parameters (composition, fluidity, asymmetry) through cyclodextrin-mediated exchange with exogenous lipids. These parameter changes make the RBCs less recognizable as senescent cells by the monocyte/macrophage system, reducing harmful uptake and inflammation even when stored beyond conventional 42-day limits, thus improving productivity without increasing harmful effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly extends the shelf life of RBCs from 42 days to up to 210 days, reducing morbidity by minimizing macrophage uptake and maintaining membrane integrity, thus enhancing the availability and safety of transfusable blood.
Implementation Method 1
exposing the donor blood and/or RBC to a quantity of a cyclodextrin composition, wherein the cyclodextrin composition comprises at least one cyclodextrin complexed with at least one exogenous lipid, in an amount sufficient to mediate the exchange of the exogenous lipids with at least one type of lipid present on an outer membrane of the RBC
Data Source
AI summary
Methods for extending the shelf life of donor blood and/or red blood cells (RBC) with a cyclodextrin composition are described. The cyclodextrin composition contains at least one cyclodextrin complexed with at least one exogenous lipid. Also described are such treated donor blood and/or RBC.